Table of Contents

company-logo

Keymed Biosciences Inc., a biotechnology company, engages in the research and development of biological therapies for the treatment of autoimmunity and oncology diseases. Its lead product candidate is CM310 for the treatment of moderate to severe atopic dermatitis (AD), asthma, chronic rhinosinusitis with nasal polyposis (CRSwNP), and chronic obstructive pulmonary disease (COPD). The company is also developing CM326, a monoclonal antibody targeting thymic stromal lymphopoietin to treat moderate-to severe AD, CRSwNP, asthma, and COPD. In addition, it develops CMG901 for the treatment of solid tumors, and gastric and gastroesophageal cancers; and CM313, a humanized monoclonal antibody to treat relapsed or refractory multiple myeloma, lymphoma and other hematological malignancies, and systemic lupus erythematosus. Further, the company is developing MIL95/CM312, a humanized monoclonal antibody targeting CD47; CM338, an antagonist antibody against mannose-binding lectinassociated serine protease-2; CM355 for the treatment of relapsed or refractory non-Hodgkin's lymphoma; CM336 to treat multiple myeloma; CM350 for the treatment of solid tumors; and CM369, an anti-CC chemokine receptor 8 monoclonal antibody. Keymed Biosciences Inc. was formerly known as 2Health Biosciences, Inc. The company was founded in 2016 and is headquartered in Chengdu, the People's Republic of China.

Keymed Biosciences Dividend Announcement

• Keymed Biosciences does not currently offer dividends, we're keeping a close eye on its growth potential and financial developments.
• Stay tuned for updates on Keymed Biosciences dividend policy and future announcements. In the meantime, explore other dividend-yielding opportunities on our website.

Keymed Biosciences Dividend History

Keymed Biosciences Dividend Yield

Keymed Biosciences current trailing twelve-month (TTM) dividend yield is -%. Interested in purchasing Keymed Biosciences stock? Use our calculator to estimate your expected dividend yield:

Keymed Biosciences Financial Ratios

P/E ratio-13.05
PEG ratio0.01
P/B ratio3.68
ROE-26.43%
Payout ratio0.00%
Current ratio4.98
Quick ratio4.81
Cash Ratio1.27

Keymed Biosciences Dividend FAQ

Does Keymed Biosciences stock pay dividends?
Keymed Biosciences does not currently pay dividends to its shareholders.
Has Keymed Biosciences ever paid a dividend?
No, Keymed Biosciences has no a history of paying dividends to its shareholders. Keymed Biosciences is not known for its dividend payments.
Why doesn't Keymed Biosciences pay dividends?
There are several potential reasons why Keymed Biosciences would choose not to pay dividends to their shareholders:

1. Growth opportunities: Companies, especially in fast-growing industries like technology, reinvest earnings into expansion, R&D, or acquisitions to fuel future growth and increase company value.

2. Tax implications: Not paying dividends can reduce the tax burden on shareholders, who may prefer to defer taxes until selling shares and realizing capital gains.

3. Investor preferences: Some investors prefer companies to reinvest profits for higher long-term returns, particularly those seeking capital appreciation over income.

4. Capital allocation priorities: Companies may allocate cash to pay down debt, fund share buybacks, or invest in projects with higher returns than dividends.

5. Market expectations: In certain sectors, like technology, reinvesting profits for growth and innovation is often prioritized over distributing dividends to shareholders.
Will Keymed Biosciences ever pay a dividend?
The decision for a company to pay dividends depends on various factors including its financial performance, growth prospects, capital allocation priorities, and shareholder preferences. While Keymed Biosciences has not paid dividends historically and has instead focused on reinvesting its earnings for growth, it's ultimately up to the company's management and board of directors to decide whether to initiate a dividend policy in the future.
Is Keymed Biosciences a dividend aristocrat?
Keymed Biosciences is not considered a Dividend Aristocrat. The term "Dividend Aristocrat" is typically used to describe a company in the S&P 500 index that has increased its dividend payouts for at least 25 consecutive years.
Is Keymed Biosciences a dividend king?
Keymed Biosciences is not classified as a "Dividend King". A Dividend King is a company that has managed to increase its dividend payouts for 50 consecutive years or more, which is an even more selective group than the Dividend Aristocrats.
Is Keymed Biosciences a dividend stock?
No, Keymed Biosciences is not considered a dividend stock. A dividend stock is a stock of a company that regularly pays out dividends to its shareholders.
How to buy Keymed Biosciences stocks?
To buy Keymed Biosciences you need a brokerage account. Open an account with a reputable brokerage firm that offers access to the stock market. Consider factors such as fees and account minimums.

Place an order: Use the brokerage's trading platform to place an order to buy Keymed Biosciences stock.

Remember that buying stocks involves risk, and it's important to carefully consider your investment goals, risk tolerance, and conduct thorough research before making any investment decisions.